Can your body become immune to Mounjaro over time?

Why 'immune to Mounjaro' is probably the wrong question to ask

The word 'immune' implies your body has learned to recognise and neutralise the medicine. That's what happens with some biological therapies over time, and it's a reasonable thing to worry about. With tirzepatide, though, the clinical picture is different. Mounjaro works by activating GIP and GLP-1 receptors, a dual pathway that regulates appetite and slows gastric emptying. These receptors don't become desensitised in a way that progressively unmakes the medicine's effect in most people who respond to it.

What the SURMOUNT trial programme showed is that weight loss does slow and eventually levels off, typically after around nine to twelve months of treatment, even on the highest doses. That's not immunity; it's the body reaching a new equilibrium. At a lower body weight, you burn fewer calories at rest, so the same energy deficit produces smaller further reductions. The medicine is still doing what it was always doing, your physiology has simply shifted around it. The detailed mechanism is explained well on the tirzepatide overview page.

There is a separate, genuinely open question about how tirzepatide interacts with immune function more broadly, one worth reading about if that's your concern. The tirzepatide and autoimmune conditions page addresses that angle directly.

The biological reasons a plateau is almost inevitable

Adaptive thermogenesis is the term clinicians use for the body's tendency to reduce its energy expenditure in response to weight loss. Lose ten kilograms and your basal metabolic rate falls, not just because you're smaller, but because the body actively defends against further loss. This is not a moral failing or a sign that treatment has given up. It is a deeply conserved biological mechanism.

On top of that, appetite often returns partially as body weight stabilises, even while remaining lower than before treatment. Mounjaro reduces appetite; it does not switch off hunger permanently. So after several months, food intake may creep up slightly while energy expenditure is lower than it was at the start. The result is a plateau that looks like the medicine has stopped working, but is better understood as a new settling point. The dedicated page on whether Mounjaro becomes less effective over time goes into this in more detail, including what the trial data shows about efficacy at 72 weeks.

Dose is also relevant. If you started at 2.5mg and haven't yet titrated upward, you may simply not yet be at the dose your prescriber is working towards. A 2.5mg pen is a starting point, its job is to let your system adjust, not to deliver the full clinical effect. Titration is a clinical decision; the Patient Information Leaflet and your prescriber set the pace.

What a prescriber actually looks at when progress has stalled

A clinical review at a plateau is not a formality. A prescriber will look at how long you've been at your current dose, whether you've reached the highest dose you've tolerated, and whether anything in your routine has shifted, sleep, stress, medicines that interact, changes in how you're eating alongside treatment. They'll also consider whether the original treatment goal is still appropriate given where you are now.

NICE's guidance on tirzepatide (TA1026) includes a review point if less than 5% weight loss is achieved after six months at the highest tolerated dose. That's a formal decision point, not a verdict on whether the medicine ever worked. It's also a reminder that ongoing research into Mounjaro's broader effects continues to shape how clinicians use it. Mounjaro remains a Black Triangle (▼) medicine, meaning the MHRA continues to collect additional safety and effectiveness data, a normal stage for recently licensed medicines.

For a read on the cost context of ongoing treatment, including what a monthly prescription typically covers and when tirzepatide might become available as a generic, the Mounjaro cost and pricing page lays that out honestly.

When to ask for a review, and what happens next

If your weight loss has stalled for eight weeks or more and nothing obvious explains it, that's a reasonable trigger for a clinical conversation. Not to demand a higher dose, but to understand the picture. A prescriber might look at whether you're at your maximum tolerated dose, whether lifestyle factors are playing a role, or whether treatment should continue at all. Some people do reach a point where the right clinical decision is to consolidate what they've achieved rather than push further.

Our prescribers review every repeat order before it's dispensed (there's no auto-renewal) so if you're treated through nume's weight management service, that review happens as a matter of course, not only when you flag a concern. You can also reach aftercare seven days a week if something feels off before your next order. The NHS guidance on weight-management injections, published by NHS England, sets out the kind of monitoring that good clinical oversight includes, it's a useful reference for understanding what a responsible service should look like. Side-effect monitoring, including the pattern described in the MHRA's Drug Safety Updates, forms part of that ongoing picture.

If you'd like a prescriber to review where you are with treatment, starting a free consultation is the straightforward next step.